Regeneron Pharmaceuticals, Inc. (REGN)

Revenue, net income and EPS are read from the company's own XBRL facts — US GAAP tags where the filer uses them, IFRS tags for a 20-F filer that does not. Where four contiguous quarterly facts exist they are summed and labelled TTM; where they do not, the latest annual figure is shown and labelled by fiscal year; where there is neither, a single quarter is shown and labelled as one. The three are never presented under the same word. A US filer never reports its fourth quarter alone, so where a TTM figure exists that quarter is the annual figure minus the nine-month stub filed with it — exact arithmetic on two reported facts, noted above wherever it was used. Figures are as reported, in the filer's own currency, and are not restated for later revisions beyond what the filer itself has amended.

Staleness is part of the reading. A company whose last periodic report is five months old is a company most of whose current position is undisclosed, whatever the price is doing.

Headlines are third-party reporting carried for context. They are not Alpha's evidence and do not feed any reading above; nothing on this page is derived from them except the co-filed tickers row, which says so.

These six fields do not come from a market feed and are not filled by one. They read ‘—’ until a published, sourced investigation covers this company, at which point they carry that investigation's documents. This company is not on Alpha’s screened list — everything above is fetched on demand from the same sources, and nothing structural is recorded for it. Current investigations →

Assembled Oct 8, 2026. A figure that could not be sourced this fetch reads ‘—’; none is carried forward from an earlier one. This page is a record, not advice, and holds no view on whether any security should be bought or sold.